Leukemia, B-Cell: all 190 studies

Page 2 of 2. Open to participants first (52), then studies with results posted, then the rest; newest registration first within each.

• CD19-CAR-T2 Cells for CD19 Positive B Cell MalignanciesCompletedNCT04605666Phase 2
• Anti-CD19 Allo-CAR-T Cells for Relapsed B Cell Malignancies After HSCTStatus unknownNCT04516551Phase 1
• Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLLActive, not recruitingNCT04515238Phase 2
• γδT Cell Infusion to Prevent Relapsed/Refractory Leukemia Rescue RelapseStatus unknownNCT04439721Early Phase 1
• Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's LymphomasTerminatedNCT04305444Phase 2
• Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and LymphomaStatus unknownNCT04271800Phase 1/2
• CD19/CD20 Dual-CAR-T in B-cell Leukemia PatientsCompletedNCT04260945Phase 1
• CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell MalignanciesStatus unknownNCT04156243Early Phase 1
• CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell MalignanciesStatus unknownNCT04156178Early Phase 1
• A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's SyndromeActive, not recruitingNCT03899337Phase 2
• ET190L1-ARTEMIS™ T Cells in Relapsed, Refractory B Cell Leukemia and LymphomaStatus unknownNCT03895944Early Phase 1
• Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell MalignanciesStatus unknownNCT03881774Phase 1
• Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLLActive, not recruitingNCT03836261Phase 3
• A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)CompletedNCT03833180Phase 1
• The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir AlafenamideTerminatedNCT03804372Phase 2
• Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients with Relapsed/refractory CLLCompletedNCT03787264Phase 2
• Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage AActive, not recruitingNCT03766763Phase 2
• Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or LymphomaWithdrawnNCT03605589Phase 1
• Immunotherapy With CD19 CART-cells for B Cell Acute Lymphoblastic LeukemiaStatus unknownNCT03599375Phase 1
• XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy SubjectsStatus unknownNCT03598179Phase 2
• Clinical Outcomes and Routine Management of Adults With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and IrelandCompletedNCT03582098
• The Clinical Research of Anti-CD20 CAR-T Cells in Patients With Refractory or Relapsed B Lymphocyte LymphomaStatus unknownNCT03576807Phase 1
• CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell TransplantationStatus unknownNCT03564977Not applicable
• Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALLStatus unknownNCT03564470Phase 2/3
• A Feasibility and Safety Study of Concomitant Therapy With Allo-CAR-T Cells and Allo-HSCT in Patients With Relapse or Refractory LeukemiaStatus unknownNCT03463928Phase 1
• Does CMV Induced Changes in NK Lymphocyte Biology Influence the Effectiveness of Antibody Therapy Used to Treat B Cell Lymphoproliferative Diseases?Status unknownNCT03417414
• A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and LymphomaStatus unknownNCT03398967Phase 1/2
• Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant TumorsStatus unknownNCT03302403Not applicable
• Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.Active, not recruitingNCT03229200Phase 4
• A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and LymphomaStatus unknownNCT03166878Phase 1/2
• A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)Active, not recruitingNCT03162536Phase 1/2
• Combination CAR-T Cell Therapy Targeting Hematological MalignanciesTerminatedNCT03125577Phase 1/2
• Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell MalignanciesWithdrawnNCT03098355Phase 1/2
• CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells MalignancyCompletedNCT03068416Phase 2
• A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell MalignanciesTerminatedNCT03050190Not applicable
• A Phase I Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell LeukemiaStatus unknownNCT02968472Phase 1
• CAR T Cells for Refractory B Cell MalignancyStatus unknownNCT02963038Phase 1/2
• Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin LymphomaCompletedNCT02920697Phase 1
• Safety Study to Assess AFM11 in Patients With Relapsed or Refractory Adult B-precursor ALLTerminatedNCT02848911Phase 1
• Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic MalignanciesStatus unknownNCT02813837Not applicable
• ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLLActive, not recruitingNCT02787369Phase 1
• Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO)CompletedNCT02689141Phase 2
• A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell LeukemiaStatus unknownNCT02672501Phase 1/2
• CD22 Redirected Autologous T Cells for ALLActive, not recruitingNCT02650414Phase 1
• Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic LymphomaWithdrawnNCT02556346Phase 1
• Multicentre Registry of Treatments and Outcomes in Patients With Chronic Lymphocytic Leukaemia (CLL) Or Indolent Non Hodgkin's Lymphoma (iNHL)TerminatedNCT02273856
• Tissue Collection for Biomarkers Determining Resistance to IbrutinibStatus unknownNCT02267590
• CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial.CompletedNCT02132624Phase 1/2
• Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO)Active, not recruitingNCT02050347Phase 1
• Vaccine Therapy for Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)Status unknownNCT01976520Phase 1
• AZD6738 First Time in Patient Multiple Ascending Dose StudyCompletedNCT01955668Phase 1
• Retrospective Study: Efficacy and Safety of Chlorambucil + Rituximab in CLL PatientsStatus unknownNCT01862445
• Efficacy and Safety Study of Bendamustine With or Without Rituximab in Chronic Lymphoproliferative DisordersCompletedNCT01832597
• A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell MalignanciesCompletedNCT01805375Phase 1
• Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedNCT01744626Phase 1
• Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic LymphomaCompletedNCT01732861Phase 1
• A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic LeukemiaActive, not recruitingNCT01683279Phase 1
• A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive TreatmentStatus unknownNCT01678430Phase 3
• Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in 17p- Chronic Lymphocytic Leukemia (CLL)CompletedNCT01675102
• Trial of Haploidentical Stem Cell Transplantation for Haematological CancersCompletedNCT01597219Phase 2
• The Effect of 25-OH-Vitamin-D3 Substitution in Patients With Malignant and Immune-hematologic DiseasesTerminatedNCT01518959Phase 3
• Improving Blood Stem Cell Collection and Transplant ProceduresCompletedNCT01517035Phase 1/2
• A Study of the Effect of Vinca Alkaloids on c-Jun N-terminal Kinase (JNK) Phosphorylation in Patients With Chronic Lymphocytic Leukemia (CLL)TerminatedNCT01463852Early Phase 1
• Phase IV Observational Study in Chronic Lymphocytic LeukemiaCompletedNCT01453062
• R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic LymphomaTerminatedNCT01446900Phase 2
• Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLLCompletedNCT01400685Phase 1
• Infusion of Allogeneic Umbilical Cord Blood-Derived Cluster of Differentiation Antigen 19 (CD19)-Specific T CellsCompletedNCT01362452Phase 1
• CLL Empirical Antibiotic RegimenCompletedNCT01279252Phase 2
• RESPeCT: Revlimid Early Stage Poor Prognosis Chronic Lymphocytic Leukaemia (CLL) TrialTerminatedNCT01127542Phase 2
• A Study of the Kinetics of Lymphoid Cells in Patients With Monoclonal B-cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL) and Healthy VolunteersCompletedNCT01117142
• Ofatumumab Cardiac Repolarization (QTc) Study in Fludarabine-Refractory Chronic Lymphocytic Leukemia SubjectsCompletedNCT01110031Phase 1
• Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell TransplantationCompletedNCT01087294Phase 1
• Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic MalignancyCompletedNCT00990587Phase 1
• Tumor Registry of Lymphatic NeoplasiaCompletedNCT00889798
• Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6)CompletedNCT00871663Phase 1
• Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell LymphomaCompletedNCT00849654Phase 1
• Safety Study of ABT-263 in Combination With Rituximab in Lymphoid CancersCompletedNCT00788684Phase 1
• A Phase I Extension Trial of Repeated Infusions of ISF35CompletedNCT00783588Phase 1
• A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35)CompletedNCT00779883Phase 1
• A Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLLCompletedNCT00772486Phase 1
• High-dose Methylprednisolone and Rituximab in High Risk B-CLLCompletedNCT00558181Phase 2
• R-CHOP and Alemtuzumab in Patients With Chronic Lymphocytic LeukemiaWithdrawnNCT00504491Phase 2
• Study Evaluating Effects of CX-3543 in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic LeukemiaWithdrawnNCT00485966Phase 2
• A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's LymphomaCompletedNCT00457782Phase 1
• A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic LeukemiaCompletedNCT00419250Phase 1
• A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid MalignanciesCompletedNCT00406809Phase 1/2
• Vitalis Study - Observational Study on the Quality of Life in Patients Under Treatment for B-Chronic Lymphocytic Leukemia (B-CLL)CompletedNCT00344825
• A Single-arm Phase II Study of Alemtuzumab in Combination With High-dose Methylprednisolone in CLL Patients With p53 DeletionCompletedNCT00292760Phase 2
• Pentostatin, and Rituximab With and Without Cyclophosphamide for Previously Untreated B-Chronic Lymphocytic LeukemiaCompletedNCT00201721Phase 2
• A Pilot Study of Pivanex in Patients With Chronic Lymphocytic LeukemiaTerminatedNCT00083473Phase 2

← Leukemia, B-Cell overview